Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


EHA 25 European Perspectives Webinar: Lymphomas

  • Invited speakers

  • Prof. dr. Peter Borchmann

    hematologist

    German Hodgkin Study Group, University Hospital Cologne, University of Cologne, Germany

  • Dr. Robert Marcus

    hematologist

    London Bridge Hospital, United Kingdom

Related items

Congress news 22/06/2020

EHA 25 European Perspectives Webinar: Multiple Myeloma & CAR-T

In this webinar, Prof. Dr. John Gribben, Prof. Dr. Valentín Ortiz and PD Prof. Dr. Dr. Udo Holtick discuss three practice changing studies on Multiple Myeloma/CAR-T. Study 1 summarised by Prof. Dr. John Gribben IXAZOMIB VS PLACEBO AS POST-INDUCTION MAINTENANCE THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) NOT UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT): PHASE 3 TOURMALINE-MM4 TRIAL Study 2 summarised by Prof. Dr. Valentín Ortiz IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121), A BCMA-TARGETED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: INITIAL KARMMA RESULTS Study 3 summarised by PD Prof. Dr. Dr. Udo Holtick LB2603 ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY   The webinar was independently produced and paid for by the MEDtalks Group of Companies.

Congress news 22/06/2020

EHA 25 European Perspectives Webinar: CLL

In this webinar, Prof. Dr. Arnon Kater, Prof. Dr. Clemens Wendtner and Prof. Dr. Davide Rossi discuss three practice changing studies on CLL. Study 1 summarised by Prof. Dr. Arnon Kater EFFICACY OF VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: PRIMARY ENDPOINT ANALYSIS OF THE INTERNATIONAL PHASE 3B TRIAL (VENICE I) Study 2 summarised by Prof. Dr. Clemens Wendtner S155: FIXED-DURATION VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: FOLLOW-UP OF EFFICACY AND SAFETY RESULTS FROM THE MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE 3 CLL14 TRIAL Study 3 summarised by Prof. Dr. Davide Rossi S 158: FIRST-LINE IBRUTINIB (IBR) + VENETOCLAX (VEN) FOR PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): EFFICACY AND SAFETY RESULTS FROM CAPTIVATE MRD COHORT   The webinar was independently produced and paid for by the MEDtalks Group of Companies.

Congress news 22/06/2020

EHA 25 European Perspectives Webinar: AML

In this webinar, Prof. Dr. Nigel Russel, MD and Prof. Dr. Gert Ossenkoppele discuss two practice changing studies on AML. Study 1 summarised by Prof. Dr. Nigel Russell MD (S144) THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IS WELL-TOLERATED AND EFFECTIVE IN AML PATIENTS: PHASE 1B RESULTS Study 2 summarised by Prof. Dr. Gert Ossenkoppele (LB2601) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VENETOCLAX WITH AZACITIDINE VS AZACITIDINE IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE THERAPY-VIALE-A   The webinar was independently produced and paid for by the MEDtalks Group of Companies.

Congress news 22/06/2020

ASCO Discussion Round III: Highlights from a European Perspective

In this third live discussion round, experts from Switzerland and Germany discuss practice-changing studies in the fields of GU, Immunoncology and Hematology with the ASCO2020 original authors.  The following authors are presenting their studies:  Dr. Thierry André Sorbonne University and Saint-Antoine Hospital, Paris, France Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study   Prof. Dr. Shaji Kumar Mayo Clinic, Rochester, MN, USA Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.   Dr. Landon Carter Brown Duke Cancer Institute, Durham, North Carolina, USA Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.   Dr. Jesus G. Berdeja Sarah Cannon Research Institute, Nashville, TN, USA Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.   Prof. Dr. Thomas Powles Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, London, UK Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.   ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.

Congress news 22/06/2020

Myeloma - Dr. Zander // Highlights EHA25

In this presentation, Dr. Zander from the Cantonal Hospital in Luzern presents his Highlights for the topic "Myeloma" from the EHA25 virtual Meeting. TOPICS NDMM: Best Triplet?             Endurance: Phase 3 VRd versus KRd NDMM: Triplet vs. Quadruplet?             High-Risk (HR) MM: SWOG1211 Trial: Phase VRd vs VRd + Elotuzumab             GMMG HD6 Trial: Phase 3 VRd vs VRd + Elotuzumab NDMM: Stamina Update: Duration of Maintenance; Tandem in HR MM   Relapsed MM:             Bispecific Antibody: Teclistamab CD3xBCMA             CART

Congress news 22/06/2020

CLL & Indolent Lymphoma - Prof. Rossi // Highlights EHA25

In this presentation, Prof. Rossi from the Oncology Institute in Southern Switzerland presents his Highlights for the topic "CLL & Indolent Lymphoma" from the EHA25 virtual Meeting. TOPICS S155: FIXED-DURATION VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: FOLLOW-UP OF EFFICACY AND SAFETY RESULTS FROM THE MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE 3 CLL14 TRIAL Othman Al-Sawaf S158: FIRST-LINE IBRUTINIB (IBR) + VENETOCLAX (VEN) FOR PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): EFFICACY AND SAFETY RESULTS FROM CAPTIVATE MRD COHORT Tanya Siddiqi S156: EFFICACY OF VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: PRIMARY ENDPOINT ANALYSIS OF THE INTERNATIONAL PHASE 3B TRIAL (VENICE I) Arnon Kater S159: ACALABRUTINIB VS IDELALISIB PLUS RITUXIMAB (IDR) OR BENDAMUSTINE PLUS RITUXIMAB (BR) IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): ASCEND FINAL RESULTS Paolo Ghia S225: ASPEN: RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB FOR PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) Meletios Dimopoulos

Congress news 22/06/2020

European clinicians share their local perspectives on practice changing studies from EHA25 Virtual

MEDtalks in association with The European Hematology Association has launched a series of four webinars, covering some of the most important practice changing studies presented at EHA25 Virtual. We invited leading European clinicians and study authors from the UK, Germany, Spain, the Netherlands and Switzerland to discuss the relevance of these studies for their local clinical practice. The webinar series was divided into the following topics: Multiple Myeloma & CAR-T, Lymphoma, CLL and AML. You can watch the webinars below: Multiple myeloma & CAR-T Webinar Lymphomas Webinar CLL Webinar AML Webinar All webinars are moderated by PD Dr. med. Jens Ulrich Rüffer. The webinars are independently produced and paid for by the MEDtalks Group of Companies.